Related Experiment Video
Updated: Jan 17, 2026
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
α-Synuclein seed amplification assay positivity beyond synucleinopathies
Ivan Martinez-Valbuena1, Sarah Fullam2, Sean O'Dowd2
1Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada; Krembil Brain Institute, University Health Network, Toronto, Ontario, M5T 0S8, Canada; Rossy Centre for PSP, Toronto Western Hospital, Toronto, Ontario, M5T 2S8, Canada.
Misfolded alpha-synuclein is found in various neurodegenerative diseases beyond Parkinson's. Cerebrospinal fluid seed amplification assays (SAAs) detect this protein, aiding in understanding disease complexity and improving diagnostics.
Area of Science:
- Neurology
- Biochemistry
- Molecular Biology
Background:
- Neurodegenerative diseases involve complex protein pathologies.
- Alpha-synuclein is implicated beyond classical synucleinopathies like Parkinson's disease.
- Seed amplification assays (SAAs) offer sensitive detection of misfolded alpha-synuclein in cerebrospinal fluid (CSF).
Purpose of the Study:
- To review the application of CSF-based alpha-synuclein SAAs in detecting co-pathology in non-synucleinopathies.
- To explore the role of alpha-synuclein in clinical heterogeneity and disease progression.
- To highlight the need for integrating co-pathologies into diagnostic and therapeutic strategies.
Main Methods:
- Focus on cerebrospinal fluid (CSF) alpha-synuclein seed amplification assays (SAAs).
- Review of studies examining alpha-synuclein co-pathology in Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, idiopathic normal pressure hydrocephalus, and traumatic brain injury.
- Analysis of evidence linking alpha-synuclein to clinical heterogeneity and disease progression.
Main Results:
- CSF alpha-synuclein SAAs detect misfolded alpha-synuclein in various neurodegenerative conditions.
- Alpha-synuclein plays a role in the clinical presentation and progression of diverse neurological disorders.
- Integrating co-pathology detection into diagnostic frameworks is increasingly supported.
Conclusions:
- CSF alpha-synuclein SAAs are valuable tools for identifying co-pathology in neurodegenerative diseases.
- Understanding alpha-synuclein's role in non-synucleinopathies is crucial for personalized medicine.
- Further research addressing knowledge gaps and assay limitations will enhance precision neurology.
